ATE252602T1 - Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen - Google Patents

Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Info

Publication number
ATE252602T1
ATE252602T1 AT97941371T AT97941371T ATE252602T1 AT E252602 T1 ATE252602 T1 AT E252602T1 AT 97941371 T AT97941371 T AT 97941371T AT 97941371 T AT97941371 T AT 97941371T AT E252602 T1 ATE252602 T1 AT E252602T1
Authority
AT
Austria
Prior art keywords
menb
vaccine compositions
mimetics
antibodies
meningococcus
Prior art date
Application number
AT97941371T
Other languages
English (en)
Inventor
Dan Granoff
Gregory R Moe
Original Assignee
Chiron Corp
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Childrens Hosp Medical Center filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE252602T1 publication Critical patent/ATE252602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1217—Neisseriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97941371T 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen ATE252602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2579996P 1996-08-27 1996-08-27
PCT/US1997/015167 WO1998008874A1 (en) 1996-08-27 1997-08-27 Monoclonal antibodies that define unique meningococcal b epitopes and their use in the preparation of vaccine compositions

Publications (1)

Publication Number Publication Date
ATE252602T1 true ATE252602T1 (de) 2003-11-15

Family

ID=21828119

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97941371T ATE252602T1 (de) 1996-08-27 1997-08-27 Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen

Country Status (7)

Country Link
US (4) US6048527A (de)
EP (1) EP0922059B1 (de)
JP (2) JP4150082B2 (de)
AT (1) ATE252602T1 (de)
CA (1) CA2264585C (de)
DE (1) DE69725739T2 (de)
WO (1) WO1998008874A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
WO2002064091A2 (en) * 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
ATE208629T1 (de) * 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
ATE252602T1 (de) * 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
WO1999010372A1 (en) 1997-08-27 1999-03-04 Chiron Corporation Molecular mimetics of meningococcal b epitopes
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
CA2353072A1 (en) * 1998-12-14 2000-06-22 Palatin Technologies, Inc. Metallopeptide combinatorial libraries and applications
US7033748B2 (en) * 1999-08-06 2006-04-25 Ivigene Corporation Identification of microbial polynucleotides expressed during infection of a host
NZ515553A (en) 1999-08-06 2005-01-28 Ivigene Corp Microbial polynucleotides expressed during infection of a host
US7049398B1 (en) * 1999-08-12 2006-05-23 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7189405B1 (en) * 1999-10-29 2007-03-13 Rice Peter A Peptide mimics of conserved gonococcal epitopes and methods and compositions using them
AU1623801A (en) * 1999-11-19 2001-05-30 Palatin Technologies, Inc. Opioid metallopeptide compositions and methods
ES2588917T3 (es) * 2000-01-17 2016-11-07 Glaxosmithkline Biologicals Sa Vacuna de VME suplementada contra meningococo
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7385025B2 (en) * 2000-12-19 2008-06-10 Palatin Technologies, Inc. Metallopeptide compounds
US20020131953A1 (en) * 2001-03-14 2002-09-19 Ut Southwestern Medical Center In situ langerhans cell vaccine
CA2439428C (en) * 2001-04-17 2012-01-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2482747C (en) * 2002-04-19 2010-06-29 Yonsei University Vaccine composition for preventing meningococcal disease
EP1411061A1 (de) * 2002-10-16 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Poly-alpha2,8-sialylsäure mimetische Peptide und ihre Verwendungen
CA2530364C (en) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
CN105777867A (zh) * 2004-05-11 2016-07-20 艾比吉诺米克斯合作公司 诱导t细胞死亡的表位
US7595307B2 (en) * 2004-06-23 2009-09-29 Children's Hospital And Research Center At Oakland Polysaccharide derivatives and uses in induction of an immune response
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US8052971B2 (en) * 2005-11-21 2011-11-08 MG Biologics Oral use of specific antibodies for intestinal health
WO2007070372A2 (en) * 2005-12-09 2007-06-21 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
EP1976554B1 (de) * 2005-12-23 2016-11-16 Children's Hospital & Research Center at Oakland De-n-acetyl-sialinsäure-antigene, antikörper dagegen und verfahren zur verwendung in der krebstherapie
AR058736A1 (es) * 2005-12-29 2008-02-20 Ct Ingenieria Genetica Biotech Peptidos mimeticos de carbohidratos y su empleo en formulaciones farmaceuticas
WO2007084856A2 (en) * 2006-01-13 2007-07-26 Baxter International Inc. Method for purifying polysaccharides
GB0606155D0 (en) * 2006-03-28 2006-05-10 Liverpool School Of Tropical M Bacterial vaccine
US8414899B2 (en) * 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
WO2009006591A1 (en) * 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Inhibitors of polysialic acid de-n-acetylase and methods for using the same
WO2009006613A1 (en) 2007-07-03 2009-01-08 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
AU2008272792B2 (en) * 2007-07-03 2014-03-06 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009065077A1 (en) * 2007-11-16 2009-05-22 Pharmain Corporation Cationic-core carrier compositions for delivery of therapeutic agents, methods of making and using the same
WO2009117409A2 (en) * 2008-03-18 2009-09-24 Merck & Co., Inc. A high throughput protein interaction assay
TW201103980A (en) * 2009-07-08 2011-02-01 Abbott Biologicals Bv Viral vaccine and use thereof
EP3246044B2 (de) 2010-08-23 2024-04-10 Wyeth LLC Stabile formulierungen von neisseria-meningitidis-rlp2086-antigenen
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
WO2012054879A1 (en) * 2010-10-22 2012-04-26 Duke University Compositions and methods for the treatment of septic arthritis, osteomyelitis, and bacteremia
EP2732457A4 (de) 2011-07-14 2015-09-16 Univ George Washington Abgaskollimation für eine massenspektrometrie mit laserablations-elektrospray-ionisation
US10598666B2 (en) * 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
WO2013132452A2 (en) 2012-03-09 2013-09-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2014179714A1 (en) * 2013-05-03 2014-11-06 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer Composições para neisseria meningitidis e métodos das mesmas
CA3184270A1 (en) * 2020-05-19 2021-11-25 Laboratory Corporation Of America Holdings Methods and systems for quantitative detection of antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DE3483957D1 (de) * 1983-11-21 1991-02-21 Wellcome Found Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen.
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) * 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
AU640118B2 (en) * 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
RU2105568C1 (ru) * 1989-12-14 1998-02-27 Нэшнл Рисерч Каунсл Оф Канада Полисахарид neisseria meningitidis с модифицированной группой b, конъюгированный антиген, вакцина против менингита группы b и способ индукции ответа антител к менингиту группы b
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
ATE252602T1 (de) 1996-08-27 2003-11-15 Chiron Corp Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
ATE208629T1 (de) * 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
WO1999010372A1 (en) 1997-08-27 1999-03-04 Chiron Corporation Molecular mimetics of meningococcal b epitopes

Also Published As

Publication number Publication date
US20040077840A1 (en) 2004-04-22
US20020197260A1 (en) 2002-12-26
EP0922059B1 (de) 2003-10-22
US7504254B2 (en) 2009-03-17
DE69725739D1 (de) 2003-12-11
US7063949B2 (en) 2006-06-20
CA2264585C (en) 2005-06-14
DE69725739T2 (de) 2004-08-05
US6642354B2 (en) 2003-11-04
JP2001500372A (ja) 2001-01-16
CA2264585A1 (en) 1998-03-05
JP4150082B2 (ja) 2008-09-17
JP2008044947A (ja) 2008-02-28
EP0922059A1 (de) 1999-06-16
US20060035284A1 (en) 2006-02-16
US6048527A (en) 2000-04-11
WO1998008874A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
ATE252602T1 (de) Meningokokkus b-epitop ausbildende monoklonale antikoerper und deren verwendung zur herstellung von impfstoffzusammenstellungen
EP1630168A3 (de) Molekular-mimetika von meningokokkalen B Epitopen
LU92488I2 (fr) Dimethyl fumarate
AU657487B2 (en) Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations
DK0680512T3 (da) Immunogent meningokok LPS og ydermembranvesikler og vaccine deraf
EP2270046A3 (de) Verfahren und Zusammensetzungen zur Behandlung von mit Hämolyse assoziierten Krankheiten
HUT68798A (en) Monomeric and dimeric antibody-fragment fusion proteins
BR9814276A (pt) Antìgenos de superfìcie
CA2439428A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
ATE182623T1 (de) Humanes serum albumin, herstellung und verwendung
Ylönen et al. IgG and IgE antibody responses to cow dander and urine in farmers with cow‐induced asthma
PT929669E (pt) Antigenios derivados das filagrinas e a sua utilizacao para o diagostico da poliartrite reumatoide
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
SE9402880D0 (sv) New peptide derivatives
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use
Ellison et al. Serologic measures in the prevention of periodontal disease
NO912823D0 (no) Fremgangsmaate for fremstilling av klasse ii-proteinet av neisseria meningitidis samt vaksiner som inneholder dette.
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
ATE223227T1 (de) Verwendung von lbp zur sepsistherapie
Harris ISOLATION AND CHARACTERIZATION OF LOW MOLECULAR WEIGHT, NON-AGGREGATED ANTIHEMOPHILIC FACTOR FROM FRESH HUMAN PLASMA.
SORVILLO THE INTERACTION OF HUMAN FIBRONECTIN WITH SUBCOMPONENT CIQ OF THE COMPLEMENT SYSTEM

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0922059

Country of ref document: EP

EEFA Change of the company name